An Aussie gastro-enterologist reported that three patients treated for severe chronic constipation with fecal transplants from healthy donors recovered coincidentally from MS. Coincidence is not causality and remission is not a cure; nevertheless 15 years is a long remission.Too late for Elvis Presley, now claimed to have died of chronic constipation. Sadly, a simple low-tech procedure like this could have turned the King of Rock and Roll around, figuratively and literally. If you are an Elvis fan and a Creationist you could sing in his honor and His honor, “Returned to sender… ” On another note, from the Freudian perspective classifying people by the association between infantile and adult behavior, you might expect Elvis to be an oral or genital type, not anal retentive.
Abstract | Fecal microbiota transplantation (FMT) has been utilized sporadically for over 50 years. In the past
few years, Clostridium difficile infection (CDI) epidemics in the USA and Europe have resulted in the increased
use of FMT, given its high efficacy in eradicating CDI and associated symptoms. As more patients request
treatment and more clinics incorporate FMT into their treatment repertoire, reports of applications outside of
CDI are emerging, paving the way for the use of FMT in several idiopathic conditions. Interest in this therapy
has largely been driven by new research into the gut microbiota, which is now beginning to be appreciated as a
microbial human organ with important roles in immunity and energy metabolism. This new paradigm raises the
possibility that many diseases result, at least partially, from microbiota-related dysfunction. This understanding
invites the investigation of FMT for several disorders, including IBD, IBS, the metabolic syndrome,
neurodevelopmental disorders, autoimmune diseases and allergic diseases, among others. The field of
microbiota-related disorders is currently in its infancy; it certainly is an exciting time in the burgeoning science
of FMT and we expect to see new and previously unexpected applications in the near future. Well-designed and
well-executed randomized trials are now needed to further define these microbiota-related conditions.